Dose accuracy and injection force dynamics of a novel disposable insulin pen

Abstract

SoloStar^® (sanofi-aventis) is a new, disposable insulin pen for the administration of insulin glargine (Lantus^®, sanofi-aventis) or insulin glulisine (Apidra^®, sanofi-aventis). SoloStar was developed to address a wide range of patient needs and demonstrates advancement over previous devices, owing to its appropriate combination of ergonomically-tested and mechanically improved features. The authors report the results of key investigations carried out by sanofi-aventis as part of the SoloStar development plan, including dose accuracy and injection force testing. Comparisons between SoloStar and two commonly used pens, FlexPen^® (Novo Nordisk) and the Humulin^®/Humalog^® pen (Eli Lilly) establish SoloStar as a state of the art pen that is suitable for most patients with diabetes.

Keywords::

• delivery device
• FlexPen^®
• insulin
• insulin delivery
• insulin pen
• Lilly Humulin^®/Humalog^® pen
• medical device
• SoloStar^®
• Type 1 diabetes
• Type 2 diabetes

Notes